24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (GetGoal-Duo1)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Lixisenatide (AVE0010)
Placebo
Insulin glargine
Pen auto-injector
Metformin
Thiazolidinedione (TZD)
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion criteria:
- Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled with insulin glargine and metformin
Exclusion criteria:
- HbA1c <7% or greater than (>)10% at screening
- At the time of screening age < legal age of majority
- Pregnant or breastfeeding women or women of childbearing potential with no effective contraceptive method
- Type 1 diabetes mellitus
- Metformin not at a stable dose of at least 1.5 gram per day for at least 3 months prior to the screening visit
- Use of oral or injectable antidiabetic or hypoglycemic agents other than metformin, sulfonylurea (SU) and TZDs (for example, alpha glucosidase inhibitor, other glucagon like peptide-1 [GLP-1] receptor agonists, dipeptidyl peptidase-IV [DPP-IV] inhibitors, insulin etc.) within 3 months prior to the time of screening, use of weight loss drugs if not at a stable dose for at least 3 months prior to the screening visit
- History of hypoglycemia unawareness
- Body Mass Index (BMI) less than or equal to (<=) 20 kilogram per square meter (kg/m^2)
- History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease, personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (for example, multiple endocrine neoplasia syndromes)
- History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening
- Hemoglobinopathy or hemolytic anemia, blood or plasma products transfusion within 3 months prior to the time of screening
- Within the last 6 months prior to screening: history of myocardial infarction, stroke, or heart failure requiring hospitalization
- Known history of drug or alcohol abuse within 6 months prior to the time of screening
- Any clinically significant abnormality identified on physical examination, laboratory tests, electrocardiogram or vital signs at the time of screening that in the judgment of the Investigator or any sub investigator precludes safe completion of the study or constrains efficacy assessment such as active malignant tumor or other major systemic diseases, presence of clinically significant diabetic retinopathy or presence of macular edema likely to require laser treatment within the study period
- Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic or diastolic blood pressure >180 millimeter of mercury (mmHg) or >110 mmHg, respectively
- Laboratory findings at the time of screening: amylase and/or lipase, alanine aminotransferase >3 times upper limit of the normal (ULN) laboratory range; total bilirubin: >1.5 times ULN (except in case of Gilbert's syndrome); hemoglobin <11 gram/deciliter and/or neutrophils <1500 per cubic millimeter (mm^3) and/or platelets <100 000/mm^3; positive test for Hepatitis B surface antigen and/or Hepatitis C antibody, positive serum pregnancy test in females of childbearing potential; and calcitonin >=20 picogram per milliliter (pg/mL) (5.9 picomole per milliliter [pmol/L])
- Patients who are considered by the Investigator or any sub investigator as inappropriate for this study for any reason (for example, impossibility to meet specific protocol requirements, such as scheduled visits, being able to do self-injections, likelihood of requiring treatment during the screening phase and treatment phase with drugs not permitted by the clinical study protocol, patient being investigator or any sub investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol etc.)
- Use of systemic glucocorticoids (excluding topical application or inhaled forms) for one week or more within 3 months prior to the time of screening
- Use of any investigational drug within 3 months prior to screening
- Renal impairment defined with serum creatinine > 1.4 mg/dL in women and > 1.5 mg/dL in men
- History of hypersensitivity to insulin glargine or to any of the excipients
- Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to): gastroparesis, unstable (that is, worsening) and not controlled (that is, prolonged nausea and vomiting) gastroesophageal reflux disease requiring medical treatment, within 6 months prior to the time of screening
- Any previous treatment with lixisenatide (for example, participation in a previous study with lixisenatide)
- Allergic reaction to any GLP-1 receptor agonist in the past (for example, exenatide, liraglutide) or to metacresol
- Additional exclusion criteria during or at the end of the run-in phase before randomization: informed consent withdrawal (patient who was not willing to continue or failed to return), mean fasting SMPG calculated from the self-measurements for the 7 days prior to Visit 12 (Week -1) was >140 mg/dL (7.8 mmol/L) and HbA1c measured at Visit 12 (Week -1) is <7% or >9%, amylase and/or lipase > 3 times the ULN at Visit 12 (Week -1), patients with fasting plasma glucose (FPG) above the threshold value described for rescue (that is, FPG >240 mg/dL [13.3 mmol/L]), patients with any adverse event, which, by the judgment of the Investigator precludes the inclusion in the double-blind randomized treatment phase, and lack of compliance to protocol or to insulin glargine treatment during the run-in phase
Sites / Locations
- Sanofi-Aventis Investigational Site Number 840223
- Sanofi-Aventis Investigational Site Number 840206
- Sanofi-Aventis Investigational Site Number 840201
- Sanofi-Aventis Investigational Site Number 840212
- Sanofi-Aventis Investigational Site Number 840215
- Sanofi-Aventis Investigational Site Number 840214
- Sanofi-Aventis Investigational Site Number 840221
- Sanofi-Aventis Investigational Site Number 840211
- Sanofi-Aventis Investigational Site Number 840230
- Sanofi-Aventis Investigational Site Number 840209
- Sanofi-Aventis Investigational Site Number 840219
- Sanofi-Aventis Investigational Site Number 840231
- Sanofi-Aventis Investigational Site Number 840208
- Sanofi-Aventis Investigational Site Number 840225
- Sanofi-Aventis Investigational Site Number 840222
- Sanofi-Aventis Investigational Site Number 840202
- Sanofi-Aventis Investigational Site Number 840229
- Sanofi-Aventis Investigational Site Number 840205
- Sanofi-Aventis Investigational Site Number 840210
- Sanofi-Aventis Investigational Site Number 840217
- Sanofi-Aventis Investigational Site Number 840228
- Sanofi-Aventis Investigational Site Number 840213
- Sanofi-Aventis Investigational Site Number 840227
- Sanofi-Aventis Investigational Site Number 032204
- Sanofi-Aventis Investigational Site Number 032205
- Sanofi-Aventis Investigational Site Number 032201
- Sanofi-Aventis Investigational Site Number 032209
- Sanofi-Aventis Investigational Site Number 032211
- Sanofi-Aventis Investigational Site Number 032202
- Sanofi-Aventis Investigational Site Number 032203
- Sanofi-Aventis Investigational Site Number 076207
- Sanofi-Aventis Investigational Site Number 076202
- Sanofi-Aventis Investigational Site Number 076205
- Sanofi-Aventis Investigational Site Number 076204
- Sanofi-Aventis Investigational Site Number 124219
- Sanofi-Aventis Investigational Site Number 124213
- Sanofi-Aventis Investigational Site Number 124208
- Sanofi-Aventis Investigational Site Number 124215
- Sanofi-Aventis Investigational Site Number 124205
- Sanofi-Aventis Investigational Site Number 124202
- Sanofi-Aventis Investigational Site Number 124218
- Sanofi-Aventis Investigational Site Number 124201
- Sanofi-Aventis Investigational Site Number 124207
- Sanofi-Aventis Investigational Site Number 124209
- Sanofi-Aventis Investigational Site Number 124217
- Sanofi-Aventis Investigational Site Number 152202
- Sanofi-Aventis Investigational Site Number 152203
- Sanofi-Aventis Investigational Site Number 152206
- Sanofi-Aventis Investigational Site Number 152204
- Sanofi-Aventis Investigational Site Number 152205
- Sanofi-Aventis Investigational Site Number 152201
- Sanofi-Aventis Investigational Site Number 170204
- Sanofi-Aventis Investigational Site Number 170201
- Sanofi-Aventis Investigational Site Number 170202
- Sanofi-Aventis Investigational Site Number 203202
- Sanofi-Aventis Investigational Site Number 203204
- Sanofi-Aventis Investigational Site Number 208202
- Sanofi-Aventis Investigational Site Number 208201
- Sanofi-Aventis Investigational Site Number 208205
- Sanofi-Aventis Investigational Site Number 233201
- Sanofi-Aventis Investigational Site Number 233203
- Sanofi-Aventis Investigational Site Number 233204
- Sanofi-Aventis Investigational Site Number 233202
- Sanofi-Aventis Investigational Site Number 250204
- Sanofi-Aventis Investigational Site Number 250206
- Sanofi-Aventis Investigational Site Number 250203
- Sanofi-Aventis Investigational Site Number 250201
- Sanofi-Aventis Investigational Site Number 250202
- Sanofi-Aventis Investigational Site Number 276201
- Sanofi-Aventis Investigational Site Number 276202
- Sanofi-Aventis Investigational Site Number 276204
- Sanofi-Aventis Investigational Site Number 348205
- Sanofi-Aventis Investigational Site Number 348202
- Sanofi-Aventis Investigational Site Number 348207
- Sanofi-Aventis Investigational Site Number 348204
- Sanofi-Aventis Investigational Site Number 348206
- Sanofi-Aventis Investigational Site Number 348203
- Sanofi-Aventis Investigational Site Number 348201
- Sanofi-Aventis Investigational Site Number 356210
- Sanofi-Aventis Investigational Site Number 356206
- Sanofi-Aventis Investigational Site Number 356204
- Sanofi-Aventis Investigational Site Number 356202
- Sanofi-Aventis Investigational Site Number 356201
- Sanofi-Aventis Investigational Site Number 356205
- Sanofi-Aventis Investigational Site Number 356208
- Sanofi-Aventis Investigational Site Number 356203
- Sanofi-Aventis Investigational Site Number 356207
- Sanofi-Aventis Investigational Site Number 356209
- Sanofi-Aventis Investigational Site Number 376202
- Sanofi-Aventis Investigational Site Number 376201
- Sanofi-Aventis Investigational Site Number 376204
- Sanofi-Aventis Investigational Site Number 376203
- Sanofi-Aventis Investigational Site Number 380201
- Sanofi-Aventis Investigational Site Number 380202
- Sanofi-Aventis Investigational Site Number 458203
- Sanofi-Aventis Investigational Site Number 458202
- Sanofi-Aventis Investigational Site Number 484201
- Sanofi-Aventis Investigational Site Number 484204
- Sanofi-Aventis Investigational Site Number 484203
- Sanofi-Aventis Investigational Site Number 484206
- Sanofi-Aventis Investigational Site Number 484205
- Sanofi-Aventis Investigational Site Number 528203
- Sanofi-Aventis Investigational Site Number 528202
- Sanofi-Aventis Investigational Site Number 528204
- Sanofi-Aventis Investigational Site Number 616202
- Sanofi-Aventis Investigational Site Number 616208
- Sanofi-Aventis Investigational Site Number 616206
- Sanofi-Aventis Investigational Site Number 616207
- Sanofi-Aventis Investigational Site Number 616205
- Sanofi-Aventis Investigational Site Number 616201
- Sanofi-Aventis Investigational Site Number 616203
- Sanofi-Aventis Investigational Site Number 840226
- Sanofi-Aventis Investigational Site Number 840216
- Sanofi-Aventis Investigational Site Number 642204
- Sanofi-Aventis Investigational Site Number 642208
- Sanofi-Aventis Investigational Site Number 642205
- Sanofi-Aventis Investigational Site Number 642203
- Sanofi-Aventis Investigational Site Number 642202
- Sanofi-Aventis Investigational Site Number 642206
- Sanofi-Aventis Investigational Site Number 642207
- Sanofi-Aventis Investigational Site Number 642201
- Sanofi-Aventis Investigational Site Number 643203
- Sanofi-Aventis Investigational Site Number 643202
- Sanofi-Aventis Investigational Site Number 710202
- Sanofi-Aventis Investigational Site Number 710201
- Sanofi-Aventis Investigational Site Number 710203
- Sanofi-Aventis Investigational Site Number 752204
- Sanofi-Aventis Investigational Site Number 752203
- Sanofi-Aventis Investigational Site Number 752205
- Sanofi-Aventis Investigational Site Number 752202
- Sanofi-Aventis Investigational Site Number 752201
- Sanofi-Aventis Investigational Site Number 158204
- Sanofi-Aventis Investigational Site Number 158201
- Sanofi-Aventis Investigational Site Number 158203
- Sanofi-Aventis Investigational Site Number 158202
- Sanofi-Aventis Investigational Site Number 804203
- Sanofi-Aventis Investigational Site Number 804201
- Sanofi-Aventis Investigational Site Number 804205
- Sanofi-Aventis Investigational Site Number 804202
- Sanofi-Aventis Investigational Site Number 804204
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Lixisenatide
Placebo
Arm Description
2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
Outcomes
Primary Outcome Measures
Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 14 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Secondary Outcome Measures
Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24
The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Change From Baseline in Glucose Excursion at Week 24
Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the standardized meal test, before study drug administration. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Change From Baseline in Average 7-Point Self Monitored Plasma Glucose (SMPG) Profile at Week 24
Patients recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime once in a week and the average value for the 7-time points was calculated. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Change From Baseline in Body Weight at Week 24
Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Change From Baseline in Average Insulin Glargine Daily Dose at Week 24
Change was calculated by subtracting the baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 1 day after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24
The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 14 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24
The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 14 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Percentage of Patients Requiring Rescue Therapy During the Double-blind Period
Routine fasting SMPG, central laboratory FPG and HbA1c values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG and HbA1c were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG >200 milligram/deciliter (mg/dL) (11.1 mmol/L) or HbA1c >9%, from Week 8 to Week 24: fasting SMPG/FPG >180 mg/dL (10.0 mmol/L) or HbA1c >8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Change From Baseline in Treatment Satisfaction Score (Sum of Items 1, 4, 5, 6, 7 and 8 of DTSQ) at Week 24
Change was calculated by subtracting baseline value from Week 24 value. DTSQ: 8-item questionnaire to assess treatment satisfaction and patient perception of hyper and hypoglycemia. Each question (Q) scored on a Likert scale from 0 to 6. Six items (Q1 and 4-8; higher score = more satisfaction) measured treatment satisfaction and were summed to calculate treatment satisfaction score which ranged from 0 (very dissatisfied) to 36 (very satisfied). Two items (Q2 and 3), which were not included, measured perceived hyperglycemia and hypoglycemia, respectively and lower scores represented good perceived blood glucose control. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00975286
Brief Title
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
Acronym
GetGoal-Duo1
Official Title
A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin
Study Type
Interventional
2. Study Status
Record Verification Date
August 2016
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
August 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of the study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to insulin glargine and metformin with or without thiazolidinediones (TZDs), over a period of 24 weeks of treatment.
The primary objective is to assess the effects of lixisenatide in comparison to placebo, when added to insulin glargine and metformin, on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24.
The secondary objectives are to assess the effects of lixisenatide on the percentage of patients reaching HbA1c less than (<) 7 percent (%) and less than or equal to (<=) 6.5%, plasma glucose (fasting, postprandial during a standardized meal challenge test, 7-point self monitored profiles), body weight, insulin glargine doses, to evaluate safety and tolerability (including anti-lixisenatide antibody assessment), and to assess the impact on treatment satisfaction using the Diabetes Treatment Satisfaction Questionnaire (state) (DTSQs) in the participating countries where it is validated.
Detailed Description
The study comprises 3 periods:
An up to 14-week screening period, which includes an up to 2-week screening phase and a 12-week run-in phase with introduction and titration of insulin glargine on top of metformin +/-TZDs.
At the end of the run-in phase, patients whose HbA1c (centralized assay) is greater than or equal to (>=) 7% and less than or equal to (<=) 9% and whose mean fasting self-monitored plasma glucose (SMPG) calculated from the self measurements for the 7 days prior to Visit 12 (Week -1) is <=140 milligram per deciliter (mg/dL) (7.8 millimole per liter [mmol/L]), would enter a 24-week double-blind randomized treatment period comparing lixisenatide to placebo (on top of insulin glargine + metformin +/- TZDs).
A 3-day safety follow up period.
Maximum duration is of 39 weeks +/- 7 days.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
446 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Lixisenatide
Arm Type
Experimental
Arm Description
2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
Intervention Type
Drug
Intervention Name(s)
Lixisenatide (AVE0010)
Intervention Description
Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Intervention Type
Drug
Intervention Name(s)
Insulin glargine
Other Intervention Name(s)
Lantus®
Intervention Description
Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.
Intervention Type
Device
Intervention Name(s)
Pen auto-injector
Intervention Description
Lantus® SoloStar® OptiClik®
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
Intervention Type
Drug
Intervention Name(s)
Thiazolidinedione (TZD)
Intervention Description
TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
Primary Outcome Measure Information:
Title
Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
Description
Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 14 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Time Frame
Baseline, Week 24
Secondary Outcome Measure Information:
Title
Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24
Description
The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Time Frame
Baseline, Week 24
Title
Change From Baseline in Glucose Excursion at Week 24
Description
Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the standardized meal test, before study drug administration. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Time Frame
Baseline, Week 24
Title
Change From Baseline in Average 7-Point Self Monitored Plasma Glucose (SMPG) Profile at Week 24
Description
Patients recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime once in a week and the average value for the 7-time points was calculated. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Time Frame
Baseline, Week 24
Title
Change From Baseline in Body Weight at Week 24
Description
Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Time Frame
Baseline, Week 24
Title
Change From Baseline in Average Insulin Glargine Daily Dose at Week 24
Description
Change was calculated by subtracting the baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Time Frame
Baseline, Week 24
Title
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Description
Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 1 day after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Time Frame
Baseline, Week 24
Title
Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24
Description
The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 14 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Time Frame
Week 24
Title
Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24
Description
The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 14 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Time Frame
Week 24
Title
Percentage of Patients Requiring Rescue Therapy During the Double-blind Period
Description
Routine fasting SMPG, central laboratory FPG and HbA1c values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG and HbA1c were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG >200 milligram/deciliter (mg/dL) (11.1 mmol/L) or HbA1c >9%, from Week 8 to Week 24: fasting SMPG/FPG >180 mg/dL (10.0 mmol/L) or HbA1c >8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Time Frame
Baseline up to Week 24
Title
Change From Baseline in Treatment Satisfaction Score (Sum of Items 1, 4, 5, 6, 7 and 8 of DTSQ) at Week 24
Description
Change was calculated by subtracting baseline value from Week 24 value. DTSQ: 8-item questionnaire to assess treatment satisfaction and patient perception of hyper and hypoglycemia. Each question (Q) scored on a Likert scale from 0 to 6. Six items (Q1 and 4-8; higher score = more satisfaction) measured treatment satisfaction and were summed to calculate treatment satisfaction score which ranged from 0 (very dissatisfied) to 36 (very satisfied). Two items (Q2 and 3), which were not included, measured perceived hyperglycemia and hypoglycemia, respectively and lower scores represented good perceived blood glucose control. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Time Frame
Baseline, Week 24
Other Pre-specified Outcome Measures:
Title
Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24
Description
The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
Time Frame
Baseline, Week 24
Title
Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia
Description
Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.
Time Frame
First dose of study drug up to 3 days after the last dose administration
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
- Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled with insulin glargine and metformin
Exclusion criteria:
HbA1c <7% or greater than (>)10% at screening
At the time of screening age < legal age of majority
Pregnant or breastfeeding women or women of childbearing potential with no effective contraceptive method
Type 1 diabetes mellitus
Metformin not at a stable dose of at least 1.5 gram per day for at least 3 months prior to the screening visit
Use of oral or injectable antidiabetic or hypoglycemic agents other than metformin, sulfonylurea (SU) and TZDs (for example, alpha glucosidase inhibitor, other glucagon like peptide-1 [GLP-1] receptor agonists, dipeptidyl peptidase-IV [DPP-IV] inhibitors, insulin etc.) within 3 months prior to the time of screening, use of weight loss drugs if not at a stable dose for at least 3 months prior to the screening visit
History of hypoglycemia unawareness
Body Mass Index (BMI) less than or equal to (<=) 20 kilogram per square meter (kg/m^2)
History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease, personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (for example, multiple endocrine neoplasia syndromes)
History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening
Hemoglobinopathy or hemolytic anemia, blood or plasma products transfusion within 3 months prior to the time of screening
Within the last 6 months prior to screening: history of myocardial infarction, stroke, or heart failure requiring hospitalization
Known history of drug or alcohol abuse within 6 months prior to the time of screening
Any clinically significant abnormality identified on physical examination, laboratory tests, electrocardiogram or vital signs at the time of screening that in the judgment of the Investigator or any sub investigator precludes safe completion of the study or constrains efficacy assessment such as active malignant tumor or other major systemic diseases, presence of clinically significant diabetic retinopathy or presence of macular edema likely to require laser treatment within the study period
Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic or diastolic blood pressure >180 millimeter of mercury (mmHg) or >110 mmHg, respectively
Laboratory findings at the time of screening: amylase and/or lipase, alanine aminotransferase >3 times upper limit of the normal (ULN) laboratory range; total bilirubin: >1.5 times ULN (except in case of Gilbert's syndrome); hemoglobin <11 gram/deciliter and/or neutrophils <1500 per cubic millimeter (mm^3) and/or platelets <100 000/mm^3; positive test for Hepatitis B surface antigen and/or Hepatitis C antibody, positive serum pregnancy test in females of childbearing potential; and calcitonin >=20 picogram per milliliter (pg/mL) (5.9 picomole per milliliter [pmol/L])
Patients who are considered by the Investigator or any sub investigator as inappropriate for this study for any reason (for example, impossibility to meet specific protocol requirements, such as scheduled visits, being able to do self-injections, likelihood of requiring treatment during the screening phase and treatment phase with drugs not permitted by the clinical study protocol, patient being investigator or any sub investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol etc.)
Use of systemic glucocorticoids (excluding topical application or inhaled forms) for one week or more within 3 months prior to the time of screening
Use of any investigational drug within 3 months prior to screening
Renal impairment defined with serum creatinine > 1.4 mg/dL in women and > 1.5 mg/dL in men
History of hypersensitivity to insulin glargine or to any of the excipients
Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to): gastroparesis, unstable (that is, worsening) and not controlled (that is, prolonged nausea and vomiting) gastroesophageal reflux disease requiring medical treatment, within 6 months prior to the time of screening
Any previous treatment with lixisenatide (for example, participation in a previous study with lixisenatide)
Allergic reaction to any GLP-1 receptor agonist in the past (for example, exenatide, liraglutide) or to metacresol
Additional exclusion criteria during or at the end of the run-in phase before randomization: informed consent withdrawal (patient who was not willing to continue or failed to return), mean fasting SMPG calculated from the self-measurements for the 7 days prior to Visit 12 (Week -1) was >140 mg/dL (7.8 mmol/L) and HbA1c measured at Visit 12 (Week -1) is <7% or >9%, amylase and/or lipase > 3 times the ULN at Visit 12 (Week -1), patients with fasting plasma glucose (FPG) above the threshold value described for rescue (that is, FPG >240 mg/dL [13.3 mmol/L]), patients with any adverse event, which, by the judgment of the Investigator precludes the inclusion in the double-blind randomized treatment phase, and lack of compliance to protocol or to insulin glargine treatment during the run-in phase
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Study Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Sanofi-Aventis Investigational Site Number 840223
City
Mesa
State/Province
Arizona
ZIP/Postal Code
85206
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840206
City
Hot Springs
State/Province
Arkansas
ZIP/Postal Code
71913
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840201
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840212
City
Mountain Home
State/Province
Arkansas
ZIP/Postal Code
72653
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840215
City
Concord
State/Province
California
ZIP/Postal Code
94520
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840214
City
Greenbrae
State/Province
California
ZIP/Postal Code
94904
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840221
City
Orlando
State/Province
Florida
ZIP/Postal Code
32835
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840211
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70808
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840230
City
Hyattsville
State/Province
Maryland
ZIP/Postal Code
20781
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840209
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20852
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840219
City
Brighton
State/Province
Michigan
ZIP/Postal Code
48114
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840231
City
Sea Girt
State/Province
New Jersey
ZIP/Postal Code
08750
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840208
City
Fargo
State/Province
North Dakota
ZIP/Postal Code
58103
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840225
City
Mentor
State/Province
Ohio
ZIP/Postal Code
44060
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840222
City
Portland
State/Province
Oregon
ZIP/Postal Code
97201-3098
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840202
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19146
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840229
City
Bristol
State/Province
Tennessee
ZIP/Postal Code
37620
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840205
City
Germantown
State/Province
Tennessee
ZIP/Postal Code
38138
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840210
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840217
City
Houston
State/Province
Texas
ZIP/Postal Code
77081
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840228
City
Houston
State/Province
Texas
ZIP/Postal Code
77081
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840213
City
Plano
State/Province
Texas
ZIP/Postal Code
75093
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 840227
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23502
Country
United States
Facility Name
Sanofi-Aventis Investigational Site Number 032204
City
Buenos Aires
Country
Argentina
Facility Name
Sanofi-Aventis Investigational Site Number 032205
City
Capital Federal
ZIP/Postal Code
1012
Country
Argentina
Facility Name
Sanofi-Aventis Investigational Site Number 032201
City
Capital Federal
ZIP/Postal Code
1425
Country
Argentina
Facility Name
Sanofi-Aventis Investigational Site Number 032209
City
Capital Federal
ZIP/Postal Code
C1056ABJ
Country
Argentina
Facility Name
Sanofi-Aventis Investigational Site Number 032211
City
Corrientes
Country
Argentina
Facility Name
Sanofi-Aventis Investigational Site Number 032202
City
Parana
ZIP/Postal Code
(E3100BBJ)
Country
Argentina
Facility Name
Sanofi-Aventis Investigational Site Number 032203
City
Rosario
ZIP/Postal Code
2000
Country
Argentina
Facility Name
Sanofi-Aventis Investigational Site Number 076207
City
Belem
ZIP/Postal Code
66073-000
Country
Brazil
Facility Name
Sanofi-Aventis Investigational Site Number 076202
City
Brasilia
ZIP/Postal Code
71625-009
Country
Brazil
Facility Name
Sanofi-Aventis Investigational Site Number 076205
City
Porto Alegre
ZIP/Postal Code
90035001
Country
Brazil
Facility Name
Sanofi-Aventis Investigational Site Number 076204
City
Sao Paulo
ZIP/Postal Code
04024-002
Country
Brazil
Facility Name
Sanofi-Aventis Investigational Site Number 124219
City
Brampton
ZIP/Postal Code
L6R 3J5
Country
Canada
Facility Name
Sanofi-Aventis Investigational Site Number 124213
City
Chatham
ZIP/Postal Code
N7L 1C1
Country
Canada
Facility Name
Sanofi-Aventis Investigational Site Number 124208
City
Chilliwack
ZIP/Postal Code
V2P 4M9
Country
Canada
Facility Name
Sanofi-Aventis Investigational Site Number 124215
City
Etobicoke
ZIP/Postal Code
M9R 4E1
Country
Canada
Facility Name
Sanofi-Aventis Investigational Site Number 124205
City
Quebec
ZIP/Postal Code
G1V 4G5
Country
Canada
Facility Name
Sanofi-Aventis Investigational Site Number 124202
City
Red Deer
ZIP/Postal Code
T4N 6V7
Country
Canada
Facility Name
Sanofi-Aventis Investigational Site Number 124218
City
Thornhill
ZIP/Postal Code
L4J 8L7
Country
Canada
Facility Name
Sanofi-Aventis Investigational Site Number 124201
City
Toronto
ZIP/Postal Code
M4R 2G4
Country
Canada
Facility Name
Sanofi-Aventis Investigational Site Number 124207
City
Toronto
ZIP/Postal Code
M9V 4B4
Country
Canada
Facility Name
Sanofi-Aventis Investigational Site Number 124209
City
Victoria
ZIP/Postal Code
V8V 4A1
Country
Canada
Facility Name
Sanofi-Aventis Investigational Site Number 124217
City
Winnipeg
ZIP/Postal Code
R3E 3P4
Country
Canada
Facility Name
Sanofi-Aventis Investigational Site Number 152202
City
Santiago
ZIP/Postal Code
7500010
Country
Chile
Facility Name
Sanofi-Aventis Investigational Site Number 152203
City
Santiago
ZIP/Postal Code
7980378
Country
Chile
Facility Name
Sanofi-Aventis Investigational Site Number 152206
City
Santiago
ZIP/Postal Code
8053095
Country
Chile
Facility Name
Sanofi-Aventis Investigational Site Number 152204
City
Santiago
ZIP/Postal Code
8360156
Country
Chile
Facility Name
Sanofi-Aventis Investigational Site Number 152205
City
Santiago
ZIP/Postal Code
8930211
Country
Chile
Facility Name
Sanofi-Aventis Investigational Site Number 152201
City
Santiago
Country
Chile
Facility Name
Sanofi-Aventis Investigational Site Number 170204
City
Barranquilla
Country
Colombia
Facility Name
Sanofi-Aventis Investigational Site Number 170201
City
Bogota
Country
Colombia
Facility Name
Sanofi-Aventis Investigational Site Number 170202
City
Bogota
Country
Colombia
Facility Name
Sanofi-Aventis Investigational Site Number 203202
City
Hradec Kralove
ZIP/Postal Code
50005
Country
Czech Republic
Facility Name
Sanofi-Aventis Investigational Site Number 203204
City
Praha 5
ZIP/Postal Code
15006
Country
Czech Republic
Facility Name
Sanofi-Aventis Investigational Site Number 208202
City
Frederiksberg
ZIP/Postal Code
2000
Country
Denmark
Facility Name
Sanofi-Aventis Investigational Site Number 208201
City
København Nv
ZIP/Postal Code
2400
Country
Denmark
Facility Name
Sanofi-Aventis Investigational Site Number 208205
City
Slagelse
ZIP/Postal Code
4200
Country
Denmark
Facility Name
Sanofi-Aventis Investigational Site Number 233201
City
Pärnu
ZIP/Postal Code
80018
Country
Estonia
Facility Name
Sanofi-Aventis Investigational Site Number 233203
City
Tallinn
ZIP/Postal Code
13415
Country
Estonia
Facility Name
Sanofi-Aventis Investigational Site Number 233204
City
Tartu
ZIP/Postal Code
50410
Country
Estonia
Facility Name
Sanofi-Aventis Investigational Site Number 233202
City
Viljandimaa
ZIP/Postal Code
71024
Country
Estonia
Facility Name
Sanofi-Aventis Investigational Site Number 250204
City
Amiens Cedex 1
ZIP/Postal Code
80054
Country
France
Facility Name
Sanofi-Aventis Investigational Site Number 250206
City
La Rochelle Cedex
ZIP/Postal Code
17019
Country
France
Facility Name
Sanofi-Aventis Investigational Site Number 250203
City
Le Creusot
ZIP/Postal Code
71200
Country
France
Facility Name
Sanofi-Aventis Investigational Site Number 250201
City
Nantes
ZIP/Postal Code
44093
Country
France
Facility Name
Sanofi-Aventis Investigational Site Number 250202
City
Pierre Benite
ZIP/Postal Code
69310
Country
France
Facility Name
Sanofi-Aventis Investigational Site Number 276201
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Sanofi-Aventis Investigational Site Number 276202
City
Mainz
ZIP/Postal Code
55116
Country
Germany
Facility Name
Sanofi-Aventis Investigational Site Number 276204
City
St. Ingbert-Oberwürzbach
ZIP/Postal Code
66386
Country
Germany
Facility Name
Sanofi-Aventis Investigational Site Number 348205
City
Balatonfüred
ZIP/Postal Code
8230
Country
Hungary
Facility Name
Sanofi-Aventis Investigational Site Number 348202
City
Budapest
ZIP/Postal Code
1036
Country
Hungary
Facility Name
Sanofi-Aventis Investigational Site Number 348207
City
Budapest
Country
Hungary
Facility Name
Sanofi-Aventis Investigational Site Number 348204
City
Debrecen
ZIP/Postal Code
4031
Country
Hungary
Facility Name
Sanofi-Aventis Investigational Site Number 348206
City
Gyula
ZIP/Postal Code
5700
Country
Hungary
Facility Name
Sanofi-Aventis Investigational Site Number 348203
City
Szeged
ZIP/Postal Code
6722
Country
Hungary
Facility Name
Sanofi-Aventis Investigational Site Number 348201
City
Zalaegerszeg
ZIP/Postal Code
8900
Country
Hungary
Facility Name
Sanofi-Aventis Investigational Site Number 356210
City
Ahmedabad
ZIP/Postal Code
380015
Country
India
Facility Name
Sanofi-Aventis Investigational Site Number 356206
City
Bangalore
ZIP/Postal Code
560043
Country
India
Facility Name
Sanofi-Aventis Investigational Site Number 356204
City
Bangalore
ZIP/Postal Code
560052
Country
India
Facility Name
Sanofi-Aventis Investigational Site Number 356202
City
Bangalore
Country
India
Facility Name
Sanofi-Aventis Investigational Site Number 356201
City
Belgaum
ZIP/Postal Code
590001
Country
India
Facility Name
Sanofi-Aventis Investigational Site Number 356205
City
Chennai
ZIP/Postal Code
600086
Country
India
Facility Name
Sanofi-Aventis Investigational Site Number 356208
City
Indore
ZIP/Postal Code
452010
Country
India
Facility Name
Sanofi-Aventis Investigational Site Number 356203
City
Karnal
ZIP/Postal Code
132001
Country
India
Facility Name
Sanofi-Aventis Investigational Site Number 356207
City
Kochi
Country
India
Facility Name
Sanofi-Aventis Investigational Site Number 356209
City
Nagpur
ZIP/Postal Code
440012
Country
India
Facility Name
Sanofi-Aventis Investigational Site Number 376202
City
Haifa
ZIP/Postal Code
31096
Country
Israel
Facility Name
Sanofi-Aventis Investigational Site Number 376201
City
Holon
ZIP/Postal Code
58100
Country
Israel
Facility Name
Sanofi-Aventis Investigational Site Number 376204
City
Kfar Saba
ZIP/Postal Code
44281
Country
Israel
Facility Name
Sanofi-Aventis Investigational Site Number 376203
City
Tel Hashomer
ZIP/Postal Code
52621
Country
Israel
Facility Name
Sanofi-Aventis Investigational Site Number 380201
City
Milano
ZIP/Postal Code
20132
Country
Italy
Facility Name
Sanofi-Aventis Investigational Site Number 380202
City
Perugia
ZIP/Postal Code
61260
Country
Italy
Facility Name
Sanofi-Aventis Investigational Site Number 458203
City
Kelantan
ZIP/Postal Code
16150
Country
Malaysia
Facility Name
Sanofi-Aventis Investigational Site Number 458202
City
Kuala Lumpur
ZIP/Postal Code
56000
Country
Malaysia
Facility Name
Sanofi-Aventis Investigational Site Number 484201
City
Cuernavaca
ZIP/Postal Code
62250
Country
Mexico
Facility Name
Sanofi-Aventis Investigational Site Number 484204
City
Durango
ZIP/Postal Code
34270
Country
Mexico
Facility Name
Sanofi-Aventis Investigational Site Number 484203
City
Guadalajara
ZIP/Postal Code
44600
Country
Mexico
Facility Name
Sanofi-Aventis Investigational Site Number 484206
City
México City
ZIP/Postal Code
14050
Country
Mexico
Facility Name
Sanofi-Aventis Investigational Site Number 484205
City
Tlalnepantla
ZIP/Postal Code
53160
Country
Mexico
Facility Name
Sanofi-Aventis Investigational Site Number 528203
City
Amsterdam
ZIP/Postal Code
1066 EC
Country
Netherlands
Facility Name
Sanofi-Aventis Investigational Site Number 528202
City
Groningen
ZIP/Postal Code
9728 NT
Country
Netherlands
Facility Name
Sanofi-Aventis Investigational Site Number 528204
City
Zwijndrecht
ZIP/Postal Code
3331 LZ
Country
Netherlands
Facility Name
Sanofi-Aventis Investigational Site Number 616202
City
Krakow
ZIP/Postal Code
31-548
Country
Poland
Facility Name
Sanofi-Aventis Investigational Site Number 616208
City
Lubin
ZIP/Postal Code
59-300
Country
Poland
Facility Name
Sanofi-Aventis Investigational Site Number 616206
City
Plock
ZIP/Postal Code
09-400
Country
Poland
Facility Name
Sanofi-Aventis Investigational Site Number 616207
City
Pulawy
ZIP/Postal Code
24-100
Country
Poland
Facility Name
Sanofi-Aventis Investigational Site Number 616205
City
Sopot
ZIP/Postal Code
81-756
Country
Poland
Facility Name
Sanofi-Aventis Investigational Site Number 616201
City
Szczecin
ZIP/Postal Code
70-506
Country
Poland
Facility Name
Sanofi-Aventis Investigational Site Number 616203
City
Zabrze
ZIP/Postal Code
41-8--
Country
Poland
Facility Name
Sanofi-Aventis Investigational Site Number 840226
City
Ponce
ZIP/Postal Code
00717
Country
Puerto Rico
Facility Name
Sanofi-Aventis Investigational Site Number 840216
City
San Juan
ZIP/Postal Code
00917
Country
Puerto Rico
Facility Name
Sanofi-Aventis Investigational Site Number 642204
City
Brasov
ZIP/Postal Code
500326
Country
Romania
Facility Name
Sanofi-Aventis Investigational Site Number 642208
City
Bucharest
ZIP/Postal Code
020725
Country
Romania
Facility Name
Sanofi-Aventis Investigational Site Number 642205
City
Deva
ZIP/Postal Code
330084
Country
Romania
Facility Name
Sanofi-Aventis Investigational Site Number 642203
City
Iasi
ZIP/Postal Code
700515
Country
Romania
Facility Name
Sanofi-Aventis Investigational Site Number 642202
City
Oradea
ZIP/Postal Code
410598
Country
Romania
Facility Name
Sanofi-Aventis Investigational Site Number 642206
City
Targu Mures
ZIP/Postal Code
540061
Country
Romania
Facility Name
Sanofi-Aventis Investigational Site Number 642207
City
Timisoara
ZIP/Postal Code
300456
Country
Romania
Facility Name
Sanofi-Aventis Investigational Site Number 642201
City
Timisoara
ZIP/Postal Code
300593
Country
Romania
Facility Name
Sanofi-Aventis Investigational Site Number 643203
City
Saratov
ZIP/Postal Code
410030
Country
Russian Federation
Facility Name
Sanofi-Aventis Investigational Site Number 643202
City
St. Petersburg
ZIP/Postal Code
194358
Country
Russian Federation
Facility Name
Sanofi-Aventis Investigational Site Number 710202
City
Cape Town
ZIP/Postal Code
7708
Country
South Africa
Facility Name
Sanofi-Aventis Investigational Site Number 710201
City
Durban
ZIP/Postal Code
4092
Country
South Africa
Facility Name
Sanofi-Aventis Investigational Site Number 710203
City
Pretoria
Country
South Africa
Facility Name
Sanofi-Aventis Investigational Site Number 752204
City
Göteborg
ZIP/Postal Code
413 45
Country
Sweden
Facility Name
Sanofi-Aventis Investigational Site Number 752203
City
Härnösand
ZIP/Postal Code
871 82
Country
Sweden
Facility Name
Sanofi-Aventis Investigational Site Number 752205
City
Luleå
ZIP/Postal Code
972 33
Country
Sweden
Facility Name
Sanofi-Aventis Investigational Site Number 752202
City
Malmö
ZIP/Postal Code
211 52
Country
Sweden
Facility Name
Sanofi-Aventis Investigational Site Number 752201
City
Stockholm
ZIP/Postal Code
111 57
Country
Sweden
Facility Name
Sanofi-Aventis Investigational Site Number 158204
City
Changhua
ZIP/Postal Code
500
Country
Taiwan
Facility Name
Sanofi-Aventis Investigational Site Number 158201
City
Taichung R.O.C.
ZIP/Postal Code
407
Country
Taiwan
Facility Name
Sanofi-Aventis Investigational Site Number 158203
City
Taichung
ZIP/Postal Code
433
Country
Taiwan
Facility Name
Sanofi-Aventis Investigational Site Number 158202
City
Tainan Hsien
ZIP/Postal Code
710
Country
Taiwan
Facility Name
Sanofi-Aventis Investigational Site Number 804203
City
Chernivtsi
ZIP/Postal Code
58022
Country
Ukraine
Facility Name
Sanofi-Aventis Investigational Site Number 804201
City
Kiev
ZIP/Postal Code
2091
Country
Ukraine
Facility Name
Sanofi-Aventis Investigational Site Number 804205
City
Kyiv
ZIP/Postal Code
31156
Country
Ukraine
Facility Name
Sanofi-Aventis Investigational Site Number 804202
City
Kyiv
Country
Ukraine
Facility Name
Sanofi-Aventis Investigational Site Number 804204
City
Vinnytsya
ZIP/Postal Code
21010
Country
Ukraine
12. IPD Sharing Statement
Citations:
PubMed Identifier
23564915
Citation
Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, Ping L, Rosenstock J. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013 Sep;36(9):2497-503. doi: 10.2337/dc12-2462. Epub 2013 Apr 5.
Results Reference
result
PubMed Identifier
31956422
Citation
Davidson JA, Stager W, Paranjape S, Berria R, Leiter LA. Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data. Clin Diabetes Endocrinol. 2020 Jan 14;6:2. doi: 10.1186/s40842-019-0088-5. eCollection 2020.
Results Reference
derived
PubMed Identifier
29974618
Citation
Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, Perfetti R, Meier JJ. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018 Dec;20(12):2821-2829. doi: 10.1111/dom.13462. Epub 2018 Aug 13.
Results Reference
derived
PubMed Identifier
25130920
Citation
Charbonnel B, Bertolini M, Tinahones FJ, Domingo MP, Davies M. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J Diabetes Complications. 2014 Nov-Dec;28(6):880-6. doi: 10.1016/j.jdiacomp.2014.07.007. Epub 2014 Jul 18.
Results Reference
derived
PubMed Identifier
23628617
Citation
Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, Ping L, Ye J, Rosenstock J. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013 Sep;36(9):2489-96. doi: 10.2337/dc12-2454. Epub 2013 Apr 29.
Results Reference
derived
Learn more about this trial
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
We'll reach out to this number within 24 hrs